Jiangsu Lanfeng Bio-chemical Co.,Ltd (SHE:002513)
China · Delayed Price · Currency is CNY 7.40
+0.24 (3.35%)
Feb 6, 2026, 3:04 PM CST
SHE:002513 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,168 | 1,765 | 1,702 | 1,444 | 1,438 | 1,320 |
Other Revenue | 27.86 | 27.86 | 39.33 | 1.61 | 5.58 | 22.23 |
| 2,196 | 1,793 | 1,742 | 1,445 | 1,444 | 1,342 | |
Revenue Growth (YoY) | -8.69% | 2.96% | 20.51% | 0.09% | 7.60% | -10.80% |
Cost of Revenue | 2,245 | 1,901 | 1,805 | 1,452 | 1,473 | 1,163 |
Gross Profit | -48.8 | -107.56 | -63.2 | -7.12 | -29.22 | 178.78 |
Selling, General & Admin | 127.28 | 129.92 | 166.7 | 103.69 | 149.85 | 173.59 |
Research & Development | 60.75 | 68.68 | 15.26 | 11.65 | 12.92 | 15.89 |
Other Operating Expenses | 8.23 | 3.9 | 4.94 | 5.76 | 6.24 | 9.88 |
Operating Expenses | 183.22 | 222.63 | 194.57 | 121.51 | 194.61 | 203.05 |
Operating Income | -232.02 | -330.18 | -257.78 | -128.63 | -223.83 | -24.27 |
Interest Expense | -62.53 | -59.53 | -26.53 | -13.55 | -22.6 | -30.82 |
Interest & Investment Income | 8.3 | 8.18 | 32.63 | 10.07 | 4.02 | 38.2 |
Currency Exchange Gain (Loss) | 7.78 | 7.78 | 1.65 | 2.75 | -2.1 | -5.88 |
Other Non Operating Income (Expenses) | 1.05 | -34.66 | -6.23 | -54.89 | -6.3 | -3.14 |
EBT Excluding Unusual Items | -277.42 | -408.41 | -256.26 | -184.26 | -250.8 | -25.9 |
Gain (Loss) on Sale of Assets | -0.15 | -0.36 | -1.46 | 1.47 | -1.92 | 23.55 |
Asset Writedown | 24.56 | - | -92.61 | - | -291.5 | -10.19 |
Legal Settlements | - | - | - | - | - | -3.25 |
Other Unusual Items | -19.04 | -26.22 | -4 | -64.18 | 5.37 | 18.57 |
Pretax Income | -271.89 | -434.84 | -354.33 | -246.97 | -538.86 | 2.77 |
Income Tax Expense | -47.37 | -81.61 | -6.6 | 73.72 | -47.67 | -12.05 |
Earnings From Continuing Operations | -224.52 | -353.23 | -347.74 | -320.69 | -491.19 | 14.82 |
Minority Interest in Earnings | 79.87 | 100.73 | 15.48 | 0 | - | - |
Net Income | -144.65 | -252.5 | -332.26 | -320.69 | -491.19 | 14.82 |
Net Income to Common | -144.65 | -252.5 | -332.26 | -320.69 | -491.19 | 14.82 |
Shares Outstanding (Basic) | 377 | 369 | 373 | 374 | 341 | 371 |
Shares Outstanding (Diluted) | 377 | 369 | 373 | 374 | 341 | 371 |
Shares Change (YoY) | 3.39% | -1.13% | -0.29% | 9.63% | -7.96% | 9.05% |
EPS (Basic) | -0.38 | -0.68 | -0.89 | -0.86 | -1.44 | 0.04 |
EPS (Diluted) | -0.38 | -0.68 | -0.89 | -0.86 | -1.44 | 0.04 |
Free Cash Flow | -340.1 | -171.06 | -851.66 | -95.43 | -77.08 | 20.58 |
Free Cash Flow Per Share | -0.90 | -0.46 | -2.28 | -0.26 | -0.23 | 0.06 |
Gross Margin | -2.22% | -6.00% | -3.63% | -0.49% | -2.02% | 13.32% |
Operating Margin | -10.56% | -18.41% | -14.80% | -8.90% | -15.50% | -1.81% |
Profit Margin | -6.59% | -14.08% | -19.08% | -22.19% | -34.02% | 1.10% |
Free Cash Flow Margin | -15.49% | -9.54% | -48.90% | -6.60% | -5.34% | 1.53% |
EBITDA | -91.49 | -207.98 | -160.01 | -33.4 | -107.55 | 99.6 |
EBITDA Margin | -4.17% | -11.60% | -9.19% | -2.31% | -7.45% | 7.42% |
D&A For EBITDA | 140.54 | 122.21 | 97.77 | 95.24 | 116.28 | 123.87 |
EBIT | -232.02 | -330.18 | -257.78 | -128.63 | -223.83 | -24.27 |
EBIT Margin | -10.56% | -18.41% | -14.80% | -8.90% | -15.50% | -1.81% |
Revenue as Reported | 2,196 | 1,793 | 1,742 | 1,445 | 1,444 | 1,342 |
Advertising Expenses | - | 8.56 | 4.79 | 2.03 | 0.28 | 2.45 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.